New radioactive drug combo takes on hard-to-treat gut and pancreatic cancers

NCT ID NCT05884255

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a radioactive drug called lutetium-177 oxodotreotide, when combined with a standard dose of octreotide, works better than a high dose of octreotide alone for people with advanced neuroendocrine tumors of the gut or pancreas. About 220 adults aged 18-75 with tumors that cannot be removed by surgery will take part. The goal is to see if the combination slows cancer growth and improves survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system neuroendocrine tumor, grade 1/2 pancreatic neuroendocrine tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, 201321, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Tianjin University Cancer Institute and Hospital

    RECRUITING

    Tianjin, Tianjin Municipality, 300060, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact